The objectives of this phase II study were to define the pCR and 5‐year DFS and OS rates associated with preoperative FEC followed by weekly docetaxel plus capecitabine, with or without trastuzumab, in patients with HER2‐negative or HER2‐positive breast cancer. Here, ERBB2 is linked to breast cancer.